Chesley Taft & Associates’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-8,905
Closed -$929K 294
2017
Q4
$929K Sell
8,905
-172,635
-95% -$19.5M 0.08% 176
2017
Q3
$26.5M Buy
181,540
+180
+0.1% +$24.5K 2.29% 5
2017
Q2
$23.6M Buy
181,360
+1,389
+0.8% +$170K 2.13% 6
2017
Q1
$22.4M Sell
179,971
-852
-0.5% -$102K 2.11% 7
2016
Q4
$20.9M Sell
180,823
-610
-0.3% -$67.9K 2.07% 7
2016
Q3
$19M Buy
181,433
+2,878
+2% +$311K 1.91% 9
2016
Q2
$17.6M Buy
178,555
+33,031
+23% +$3.42M 1.81% 10
2016
Q1
$14.6M Sell
145,524
-41,690
-22% -$4.29M 1.54% 16
2015
Q4
$22.4M Sell
187,214
-14,332
-7% -$1.66M 2.36% 5
2015
Q3
$21.8M Buy
201,546
+5,535
+3% +$687K 2.38% 5
2015
Q2
$22.7M Buy
196,011
+225
+0.1% +$25.7K 2.31% 4
2015
Q1
$22.6M Buy
195,786
+5,710
+3% +$682K 2.32% 4
2014
Q4
$21.3M Buy
190,076
+350
+0.2% +$36.9K 2.15% 5
2014
Q3
$18M Buy
189,726
+18,190
+11% +$1.64M 1.88% 8
2014
Q2
$14.7M Buy
171,536
+166,366
+3,218% +$12.7M 1.52% 12
2014
Q1
$361K Sell
5,170
-400
-7% -$31.7K 0.04% 202
2013
Q4
$471K Sell
5,570
-650
-10% -$51.4K 0.05% 214
2013
Q3
$479K Hold
6,220
0.05% 208
2013
Q2
$364K Buy
+6,220
New +$374K 0.04% 219

Other funds holding CELG

Chesley Taft & Associates's CELG Position: Q1 2018 in Review

Chesley Taft & Associates sold out of Celgene Corp (CELG) in Q1 2018, closing a stake of 8,905 shares — an estimated $929K sold.

Chesley Taft & Associates first reported a position in CELG in Q2 2013 and held it in 19 quarters. The position peaked at $26.5M in Q3 2017. 1,397 funds tracked by Wall St. Rank hold CELG as of Q1 2018.

  • Chesley Taft & Associates reported no remaining Celgene Corp position as of Q1 2018 after selling out during the quarter.
  • Chesley Taft & Associates sold 8,905 Celgene Corp shares in Q1 2018, an estimated $929K.
  • Chesley Taft & Associates first reported a position in Celgene Corp in Q2 2013 and held it in 19 quarters.
  • Chesley Taft & Associates's Celgene Corp position peaked at $26.5M in Q3 2017.
  • 1,397 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2018.

Based on Chesley Taft & Associates's 13F filing for Q1 2018, filed 11 Apr 2018.